Patent intelligence · WO
WO 2021058549
ANTAGONISTE GRPR RADIOMARQUÉ POUR L'UTILISATION COMME AGENT THÉRAGNOSTIQUE
ANTAGONISTE GRPR RADIOMARQUÉ POUR L'UTILISATION COMME AGENT THÉRAGNOSTIQUE
Patent details — WO 2021058549
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Apr 1, 2021
- Expiration
- Mar 27, 2041
- CPC classes
- A61K 51/ 08 A I, A61K/51088, A61P 35/ 00 A I, A61P/3500
Quick answer
WO 2021058549 (ANTAGONISTE GRPR RADIOMARQUÉ POUR L'UTILISATION COMME AGENT THÉRAGNOSTIQUE) is held by ADVANCED ACCELERATOR APPLICATIONS ITALY SRL [IT]. Status: granted. Granted Apr 1, 2021. Expires Mar 27, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 51/ 08 A I, A61K/51088, A61P 35/ 00 A I, A61P/3500
More from ADVANCED ACCELERATOR APPLICATIONS ITALY SRL [IT]
Related pharmaceutical patents in our USPTO index.
-
EP 4541380
STABILE KONZENTRIERTE RADIONUKLID-KOMPLEX-LÖSUNGEN
granted -
CA 3235923
PROCEDES DE SYNTHESE A GRANDE ECHELLE DE COMPLEXES DE RADIONUCLEIDES
granted -
CA 3240096
POLYTHERAPIE POUR LE TRAITEMENT DU CANCER DU POUMON
granted -
CA 3234495
POLYTHERAPIE DE COMPLEXE DE RADIONUCLEIDES
granted -
CA 3215723
PROCEDES DE DIAGNOSTIC DU CANCER DE LA PROSTATE
granted -
CA 3202908
ANTAGONISTE D'INTEGRINES ALPHA-V BETA-3 ET/OU ALPHA-V BETA-5 RADIOMARQUE DESTINE A ETRE UTILISE EN TANT QU'AGENT THERAGNOSTIQUE
granted -
US 2022072166
METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS
granted -
WO 2022043557
MÉTHODE DE TRAITEMENT DE CANCERS EXPRIMANT LE PSMA
granted
Frequently asked questions
What is US patent 2021058549?
WO 2021058549 (ANTAGONISTE GRPR RADIOMARQUÉ POUR L'UTILISATION COMME AGENT THÉRAGNOSTIQUE) is held by ADVANCED ACCELERATOR APPLICATIONS ITALY SRL [IT]. Status: granted. Granted Apr 1, 2021. Expires Mar 27, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2021058549?
ADVANCED ACCELERATOR APPLICATIONS ITALY SRL [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2021058549 expire?
Our index shows an expiration date of Mar 27, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.